Scopolamine butylbromide (also known as hyoscine butylbromide) is manufactured from scopolamine, a naturally occurring antispamodic agent extracted from the plant Duboisia.1 First marketed in 1952,2 it is on the World Health Organisation’s List of Essential Medicines and is widely available in many countries both as a prescription and over the counter medicine.
Its main use is to treat spasmodic activity in the digestive system, menstrual cramps, esophageal spasms, renal colic and bladder spasms, and it can be administered orally, intravenously or as depot injection.3
MECHANISM OF ACTION
Scopolamine butylbromide binds to muscarinic M3 receptors in the gastrointestinal tract antagonizing the effect of acetylcholine in these receptors, preventing smooth muscle contraction. This reduces the spasms and therefore the pain caused by them. Therefore, although it is used to alleviate symptomatic pain, N-Butylbromide scopolamine is not classified as a conventional analgesic.4
C2 PHARMA is the exclusive distributor of N-Butylbromide scopolamine manufactured in Germany by Boehringer Ingelheim. The API is produced through extraction from Duboisia.
- Ullrich, S.F.; Hagels, H.; Kayser, O. Phytochem. Rev. 2016, 16, 333-356.
- Patent DE 856890, 1952.
- Tytgat, G.N. Drugs, 2012, 67, 1343-1357.
- Gyermek, L. In: Pharmacology of antimuscarinic agents, 1997, CRS press, p.52.